Evidence map›Paper›PMID 36568709›Full record

ArticleBMJ medicine2022

Burden and treatment of chronic obstructive pulmonary disease among people using illicit opioids: matched cohort study in England.

Dan Lewer, Sharon Cox, John R Hurst, Prianka Padmanathan, Irene Petersen, Jennifer K Quint

Abstract read
In one paragraph

Article in BMJ medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dan LewerCollaborative Centre for Inclusion Health, University College London, London, UK.ORCID 0000-0003-3698-7196
Sharon Cox *Institute of Epidemiology and Healthcare, University College London, London, UK.ORCID 0000-0001-8494-5105
John R Hurst *UCL Respiratory, University College London, London, UK.ORCID 0000-0002-7246-6040
Prianka Padmanathan *Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0003-1292-6575
Irene Petersen *Department of Primary Care and Population Health, University College London, London, UK.ORCID 0000-0002-0037-7524
Jennifer K Quint *National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-0149-4869

Funding

Medical Research Council MR/N00616X/1
6 · The paper itself

Abstract

Objective: To understand the burden of chronic obstructive pulmonary disease among people who use illicit opioids such as heroin, and evaluate inequalities in treatment. Design: Cohort study. Setting: Patients registered at primary care practices in England. Participants: 106 789 patients in the Clinical Practice Research Datalink with illicit opioid use recorded between 2001 and 2018, and a subcohort of 3903 patients with a diagnosis of chronic obstructive pulmonary disease. For both cohorts, the study sampled a comparison group with no history of illicit opioids that was matched by age, sex, and general practice. Main outcome measures: In the base cohort: diagnosis of chronic obstructive pulmonary disease and death due to the disease. In the subcohort: five treatments (influenza vaccine, pneumococcal vaccine, pulmonary rehabilitation, bronchodilators or corticosteroids, and smoking cessation support) and exacerbations requiring hospital admission. Results: 680 of 106 789 participants died due to chronic obstructive pulmonary disease, representing 5.1% of all cause deaths. Illicit opioid use was associated with 14.59 times (95% confidence interval 12.28 to 17.33) the risk of death related to chronic obstructive pulmonary disease, and 5.89 times (5.62 to 6.18) the risk of a diagnosis of the disease. Among patients with a new diagnosis, comorbid illicit opioid use was associated with current smoking, underweight, worse lung function, and more severe breathlessness. After adjusting for these differences, illicit opioids were associated with 1.96 times (1.82 to 2.12) times the risk of exacerbations requiring hospital admission, but not associated with a substantially different probability of the five treatments. Conclusions: Death due to chronic obstructive pulmonary disease is about 15 times more common among people who use illicit opioids than the general population. This inequality does not appear to be explained by differences in treatment, but late diagnosis of the disease among people who use illicit opioids might contribute.

Indexed as

EpidemiologyHealthcare DisparitiesHealth servicesPrimary health carePulmonary disease, chronic obstructiveSubstance-related disorders

Identifiers

PMID36568709
PMCPMC9770021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.